Rockefeller Capital Management
SNDX icon

Rockefeller Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Rockefeller Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75K Buy
3,209
+2,737
+580% +$59.5K ﹤0.01% 3032
2025
Q4 		$9.92K Buy
+472
New +$8.23K ﹤0.01% 3802
2023
Q1 		– Sell
-113
Closed -$2K – 3627
2022
Q4 		$2K Hold
113
– – ﹤0.01% 3606
2022
Q3 		$2K Hold
113
– – ﹤0.01% 3628
2022
Q2 		$2K Buy
+113
New +$1.88K ﹤0.01% 3828

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Rockefeller Capital Management's SNDX Position: Q1 2026 in Review

Rockefeller Capital Management increased its Syndax Pharmaceuticals (SNDX) stake by 580% in Q1 2026, buying an estimated $59.5K and bringing the position to 3,209 shares worth $75K. The position accounts for ﹤0.01% of the portfolio, ranked #3032.

Rockefeller Capital Management first reported a position in SNDX in Q2 2022 and has held it in 5 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Rockefeller Capital Management held 3,209 shares of Syndax Pharmaceuticals worth $75K as of Q1 2026.
  • Rockefeller Capital Management bought 2,737 Syndax Pharmaceuticals shares in Q1 2026, an estimated $59.5K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3032 holding.
  • Rockefeller Capital Management first reported a position in Syndax Pharmaceuticals in Q2 2022 and has held it in 5 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.